Literature DB >> 3001120

A modified immunofluorescence test for Epstein-Barr virus-specific IgM antibody.

G B Harnett, C A Palmer, M R Bucens.   

Abstract

The fluorescent antibody (FA) test for Epstein-Barr virus (EBV)-specific IgM antibody was improved by the use of sodium butyrate to induce a higher level of EBV antigen expression in P3HR-1 slide preparations and by removal of rheumatoid factor (RF) and IgG antibodies from test sera by means of adsorption with suspensions of Sepharose-IgG and Streptococcus pyogenes strain AR1. This method was compared with the Paul-Bunnell test (PB) on 1106 sera submitted to a routine virus diagnostic laboratory for infectious mononucleosis serology and 96.4% of sera showed concordant results. Thus the EBV-IgM-FA method was suitable for routine diagnostic use. However, it proved helpful to test EBV-IgM positive sera by PB to assist in the detection of cross-reacting IgM antibodies sometimes present.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3001120     DOI: 10.1016/0166-0934(85)90004-7

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  3 in total

1.  Development and evaluation of an Epstein-Barr virus (EBV) immunoglobulin M enzyme-linked immunosorbent assay based on the 18-kilodalton matrix protein for diagnosis of primary EBV infection.

Authors:  K H Chan; R X Luo; H L Chen; M H Ng; W H Seto; J S Peiris
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

2.  Seroprevalence of Antibodies to Ross River and Barmah Forest Viruses: Possible Implications for Blood Transfusion Safety After Extreme Weather Events.

Authors:  Helen Faddy; Melanie Dunford; Clive Seed; Andrew Olds; David Harley; Melinda Dean; Vanessa Racloz; Suzi McCarthy; David Smith; Robert Flower
Journal:  Ecohealth       Date:  2014-12-24       Impact factor: 3.184

3.  The distribution of antibodies to HHV-6 compared with other herpesviruses in young children.

Authors:  T J Farr; G B Harnett; G R Pietroboni; M R Bucens
Journal:  Epidemiol Infect       Date:  1990-12       Impact factor: 2.451

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.